EVENTS|NEWS|CONTACT|DONATE

Gastric Cancer
Accelerate Research
Patient Resources
Nutrition
- Eating and Healing
- Gesundheit Kitchen
  - Watch Episodes
  - Printable Recipes
Ways to Give
About Us

Read Our Newsletter

Gastric Cancer
Accelerate Research
Patient Resources
Nutrition
- Eating and Healing
- Gesundheit Kitchen
  - Watch Episodes
  - Printable Recipes
Ways to Give
About Us

Day

July 14, 2020

RemeGen Co., Ltd. Announced New RC48-ADC Data in Patients with Advanced Gastric Cancer at ASCO

RemeGen announced a 24% response rate in a clinical trial of its antibody drug conjugate RC48 in patients with HER-2 positive gastric...

Social Media

Newsroom

For press inquiries about the Gastric Cancer Foundation, please contact: Mediainfo@gastriccancer.org

Categories

Foundation News
Press Releases
Research News

Tags

adenocarcenoma advanced stage alcohol antibody biomarker blood chemoradiotherapy chemotherapy clinical trial clinical trials detection drugs endoscopy Epstein-Barr esophagogastric FDA gastrectomy gastric cancer registry gastroesophageal genes heartburn helicobacter pylori HER2 immunotherapy keytruda lonsurf metastatic nutrition peritoneal postoperative prevention proton pump inhibitor recovery recurrence research risk screening side-effects studies surgery survival treatment tumor virus women

Gastric Cancer Foundation

Tax ID 27-2978173

info@gastriccancer.org

PO Box 338
Millbrae, CA 94030

For Deliveries:
Gastric Cancer Foundation
501 Broadway, #338
Millbrae, CA 94030-1907

Site Map

Gastric Cancer
Accelerate Research
Patient Resources
Nutrition
- Eating and Healing
- Gesundheit Kitchen
  - Watch Episodes
  - Printable Recipes
Ways to Give
About Us

Social Feed

Gastric Cancer Foundation

3 days ago

When combined with best supportive care, the multi-kinase inhibitor regorafenib produced improvements in both overall survival and progression-free survival in a trial that included gastric cancer patients.www.oncologynewscentral.com/article/regorafenib-improves-survival-in-hard-to-treat-gastric-cancer ... See MoreSee Less

View on Facebook

· Share

Share on Facebook Share on Twitter Share on Linked In Share by Email

Gastric Cancer Foundation

6 days ago

Tune in for another in our Foodie Friday series focusing on healthy eating during the holidays! With Christmas around the corner, Chef Hans shares a delicious, nutritious recipe for rainbow roasted carrots. Be on the lookout for Hans' "quick seasoning" salt recipe that results in a quick, easy, dish full of essential vitamins. gastriccancer.org/video/roasted-rainbow-carrots/ ... See MoreSee Less

View on Facebook

· Share

Share on Facebook Share on Twitter Share on Linked In Share by Email

Gastric Cancer Foundation

7 days ago

“We are increasingly understanding that gastric cancer is more than one disease,” says John L. Marshall, chief medical officer of the Lombardi Comprehensive Cancer Center at Georgetown University. Learn more in this video from Cancer Network. ... See MoreSee Less

Different Treatment Algorithms for Gastric Cancers May Improve Outcomes

www.cancernetwork.com

Additional genetic testing measures and targeted therapies may improve outcomes for patients with diverse molecular subgroups of gastric cancers.

View on Facebook

· Share

Share on Facebook Share on Twitter Share on Linked In Share by Email

Gastric Cancer Foundation

1 week ago

A trial in Taiwan found that participants who had H. pylori testing along with a fecal immunochemical test (FIT) to detect colorectal cancer had significantly lower rates of gastric cancer than did people who had FIT alone. ... See MoreSee Less

H. Pylori Testing Did Not Reduce Gastric Cancer Incidence, Mortality

www.medpagetoday.com

Gastric cancer incidence was lower after adjusting for certain factors in post hoc analyses

View on Facebook

· Share

Share on Facebook Share on Twitter Share on Linked In Share by Email

Gastric Cancer Foundation

1 week ago

In a clinical trial presented at ESMO - European Society for Medical Oncology, the bispecific antibody zanidatamab from Jazzpharma posted a 59% survival rate at 30 months in patients with HER2-positive gastric cancer. ... See MoreSee Less

ESMO: Jazz HER2 bispecific posts 59% survival at 30 months in gastric cancer

www.fiercebiotech.com

Jazz Pharmaceuticals has posted fresh phase 2 data on zanidatamab that show the HER2-targeted bispecific antibody kept 59% of people with metastatic gastroesophageal cancer (mGEA) alive for at | Jazz ...

View on Facebook

· Share

Share on Facebook Share on Twitter Share on Linked In Share by Email

Subscribe to Our Newsletter

We’ll deliver our monthly newsletter to your Inbox with Foundation updates, news about cutting edge research and trends in the field, and how to make a difference.

© 2024 Gastric Cancer Foundation. All Rights Reserved.

EVENTS | NEWS | CONTACT | DONATE

Please join with us to fuel the next wave of progress.

Your support today will honor the memories of those we have lost and create much-needed hope for those who are bravely facing the disease today. Contributions are tax-deductible.

Please join with us to fuel the next wave of progress. Support our 2024 Fundraising Campaign.

Your support today will honor the memories of those we have lost and create much-needed hope for those who are bravely facing the disease today. Contributions are tax-deductible.

Together, we will defeat stomach cancer.

Together, we will defeat stomach cancer.

MORE INFO DONATE

X